EcoDrugPlus

Protein Tyrosine Kinase 2 Beta, A

Ensembl ID : ENSDARG00000022841
Gene Symbol: PTK2BA
9 Enzyme and pathways 5 Cross references
142 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSDARG00000039577
Gene Symbol: PTK2BB
5 Cross references
196 Possible Orthologues:

Protein Tyrosine Kinase 2aa

Ensembl ID : ENSDARG00000100456
Gene Symbol: PTK2AA
3 Cross references
243 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSDARG00000020334
Gene Symbol: PTPN11A
5 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSDARG00000076624
Gene Symbol: PTPRB
3 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSDARG00000010477
Gene Symbol: P2RX3A
4 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSDARG00000029718
Gene Symbol: P2RX3B
5 Cross references
201 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSDARG00000042440
Gene Symbol: P2RX7
9 Enzyme and pathways 5 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSDARG00000105281
Gene Symbol: P2RY1
12 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSDARG00000069945
Gene Symbol: P2RY12
12 Enzyme and pathways 5 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2, Tandem Duplicate 1

Ensembl ID : ENSDARG00000099915
Gene Symbol: P2RY2.1
8 Enzyme and pathways 5 Cross references
187 Possible Orthologues:

Purinergic Receptor P2y2, Tandem Duplicate 2

Ensembl ID : ENSDARG00000104927
Gene Symbol: P2RY2.2
5 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).